advanced search

SHL Group

SHL Group provides solutions for the design, development and manufacture of drug delivery devices such as autoinjectors, pen injectors, and inhalers. It offers final assembly, labelling and packaging services for its injection products, and services for medtech and patient care solutions.


Visit Website

Switzerland
SHL Medical AG
Gubelstrasse 22
6300 Zug
Switzerland

Phone / Contact

T: +41 41 368 00 00
E: [email protected]

Connect

SHL Group is a solutions provider in the design, development and manufacture of a variety of products in the pharmaceutical and healthcare industries. In drug delivery, the company’s products include re-usable and disposable injectors that can accommodate high volumes and high viscosities, and can be enhanced with digital technology.

SHL Group consists of:

  • SHL Medical, which designs, develops and manufactures advanced drug delivery devices, and also provides final assembly, labelling and packaging services for pharmaceutical and biotech companies worldwide
  • SHL Healthcare, which develops and manufactures equipment solutions for home, hospital and long-term care
  • SHL Technologies, which provides contract manufacturing and engineering services for the production of complex medtech and industrial products.

SHL is best known for its portfolio of autoinjectors and technologies for self-injection, including the Molly® family of autoinjectors, the Rotaject® technology for high-volume and high-viscosity formulations, and the Needle Isolation Technology (NIT®), a unique safety solution for cartridge-based auto injectors.

SHL Group is privately owned. It was founded in 1989 and now employs more than 4,000 people globally. SHL works with the majority of the world’s top 25 largest pharma companies.

0

SHARE

Articles by SHL Group

PREFILLED SYRINGES
Gene Rhode Fuensalida Pantig
ADDRESSING COMPLEX BIOLOGICS WITH RATIONAL DRUG DEVICE DESIGN
Gene Rhode Fuensalida Pantig reviews drug development over the years, the discovery of biologics as therapeutic agents and the emergence of autoinjectors, in correspondence with Hans Lin, PhD, a Research Fellow from Academia Sinica, Taiwan.
INJECTION
Michael McGowan
30 YEARS IN THE MAKING – AN INSIDE PERSPECTIVE ON THE EMERGENCE OF AUTOINJECTORS
Michael McGowan, Director of Market Intelligence at SHL Group, gives a perspective on the emergence of the autoinjector as a key component of the drug delivery industry, in the context of SHL celebrating its 30th anniversary this year – a journey of rapid development that reflects the growing demand for advanced drug delivery systems in the healthcare market. 
INDUSTRIALISATION
Gilbert Fluetsch
EXPANDING AUTOMATION CAPACITY FOR HIGH AND LOW VOLUMES
Gilbert Fluetsch and Lucy Chung look at how automation and assembly services can best evolve and adapt to industry standards and market demands, whilst delivering consistently at high quality and in a timely manner.
CONNECTIVITY
Dr Ramin Rafiei
MACRO TRENDS ACCELERATING THE ADOPTION OF CONNECTIVITY IN DRUG DELIVERY
Ramin Rafiei argues that connected therapeutics – the augmentation of drugs through sensors and connectivity – are now a clinical source for real-world data and provide an opportunity to bridge the efficacy-to-effectiveness gap. This next frontier in drug delivery, powered by connected therapeutics, will be data-driven, personalised, outcomes-based and accessible.
PREFILLED SYRINGES
SOLUTIONS FOR HIGH-VOLUME DRUG DELIVERY
SHL Group introduces the high-volume variation of its Molly® family of products, the Molly® 2.25, and discusses more broadly the advantages that the Molly® business model offers to pharmaceutical and biotech clients.
PREFILLED SYRINGES
Michael McGowan
VOICE OF CUSTOMER RESEARCH – A CUSTOMER-CENTRIC APPROACH TO STRATEGY DEVELOPMENT
Michael McGowan discusses SHL’s view on adapting to the shifts in market needs and stakeholder priorities in the pharma and biotech sectors, and details how SHL has implemented a “voice of customer” market research programme to ensure it provides the best possible service for its customers.
PREFILLED SYRINGES
FINAL ASSEMBLY, LABELLING & PACKAGING
For the development of combination products, pharma and biotech companies have the option to establish an assembly and packaging infrastructure internally or to outsource to a contract manufacturing organisation. One such organisation, SHL, explains what the benefits are of using a manufacturing partner and outlines what it can offer in terms of an integrated process.
PREFILLED SYRINGES
INJECTING HIGH VOLUME, HIGH VISCOSITY DRUGS
SHL details its latest offerings in the world of biologics, as well as its partnership with QuiO, a speciality digital healthcare start-up, to develop injectables in the connected healthcare space.
PREFILLED SYRINGES
THE MAKINGS OF INNOVATION IN ADVANCED DRUG DELIVERY
In the context of recent industry trends and market demands, including the emergence of biosimilars and increasingly viscous formulations, SHL provides an update on its portfolio of auto-injector products, including two new devices, Maggie® and Bertha™.
CONNECTIVITY
NOT JUST ANOTHER GADGET: INSIGHTS INTO DEVELOPING DIGITAL SOLUTIONS THAT WORK
Connected devices are increasingly widespread but their actual value and usefulness can sometimes get ignored. SHL Group believes that addressing four key questions is the way to avoid this happening in healthcare.
INJECTION
Jochen Ratjen
SAFEGUARDING USER NEEDS: THE LONG-TERM LEGACY OF SHL’S PATIENT-CENTRIC DESIGNS
Jochen Ratjen talks about his personal experiences, what patient-centricity means to SHL, and how SHL’s designs are moving ahead with the changing trends.
CONNECTIVITY
Christian Keller
THE ADD-ON APPROACH TO CONNECTIVITY
William Cirillo and Christian Keller describe a simple add-on connected digital platform that can work with an existing delivery device. Digital health is an umbrella term that covers a lot of different applications of technology in the health industry. From wearable sensors and electronic health records to health apps, connected and digital solutions are becoming more accepted.
PREFILLED SYRINGES
THE DEVELOPMENT OF THE MOLLY® PLATFORM
SHL Group explores the growth of the Molly® family of drug delivery devices as an example of how the auto injector market has changed over the last five years, and looks to the future.
CONNECTIVITY
COMPANY SHOWCASE: SHL
SHL Group, the world’s largest privately owned designer, developer and manufacturer of advanced drug delivery systems, has been recently venturing into the field of connected devices.
CONNECTIVITY
EMBRACING THE FUTURE: CONNECTED DRUG DELIVERY SOLUTIONS
SHL Group explore the opportunities that the advance of digital health can bring to pharma companies, using a connected device solution to illustrate how connectivity can improve adherence to medication.
PREFILLED SYRINGES
INNOVATIVE ADVANCED DRUG DELIVERY PRODUCTS AND SERVICES THAT SATISFY FUNDAMENTAL NEEDS
SHL Group first explores the importance of fundamental design principles in injector design, as exemplified by the Molly® auto injector.
PREFILLED SYRINGES
AUTO INJECTORS & PEN INJECTORS: A USER-CENTRIC DESIGN APPROACH
SHL Group provides insights into its injection device design processes and culture, emphasising the focus on the patient throughout the design journey.
INTERVIEW
Jochen Ratjen
JOCHEN RATJEN, SHL GROUP
Jochen Ratjen shares his insights when approaching the design and development of user-centric autoinjectors.
Top

W3 Total Cache is currently running in Pro version Development mode.